Delivery Order SPE2DR25D1100-SPE2DR26FCS8V
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,950.54 to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 mL auto-injector units on October 23, 2025, with completion scheduled for October 24, 2025. This competitively awarded, firm fixed-price delivery order represents a medical pharmaceutical supply to support federal healthcare operations. The product will be delivered from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $1,085.32 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with performance completion targeted for November 3, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be fulfilled from...
- The Defense Logistics Agency awarded a $1,167.28 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 50 mg/0.5 ml auto-injector units, with a completion date of September 15, 2025. This non-set-aside competitive award represents a single delivery order transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a $1,494.88 delivery order to AmerisourceBergen Drug Corp for XYOSTED 50 mg/0.5 mL auto-injector supplies, with an ultimate completion date of June 20, 2025. This non-set-aside, firm fixed price delivery order was issued on June 18, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $1,655.80 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector units on July 28, 2025, with completion expected by July 29, 2025. This delivery order represents a firm fixed-price purchase with no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a $1,365.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector pharmaceutical supplies. This non-set-aside award, issued on August 25, 2025, with completion targeted for August 26, 2025, represents a single delivery transaction under AmerisourceBergen's existing DLA contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,204.01 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector supplies on November 3, 2025, with completion expected by November 4, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded transaction for pharmaceutical supplies to support federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered...
- The Defense Logistics Agency awarded a $1,866.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Xyosted 50 mg/0.5 mL auto-injector units, with a completion date of November 19, 2025. This non-set-aside competitive award represents a single delivery order for pharmaceutical products under AmerisourceBergen's larger contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency (DLA) awarded a $1,629.66 delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 mL auto-injector supplies on May 8, 2025, with completion scheduled for May 9, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen's Corporate Office...
- The Defense Logistics Agency awarded a $2,665.27 delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 ml auto-injector supplies on September 16, 2025, with completion targeted for September 17, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitively awarded order fulfilled from AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's facility in...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FCS8VDelivery Order
The Defense Logistics Agency awarded a $1,218.87 delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 ml auto-injector vials, with a completion date of December 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a single delivery order under AmerisourceBergen's existing indefinite delivery contract vehicle. The product will be performed and delivered from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a leading pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare systems and other government agencies including the Defense Health Agency and U.S. Coast Guard. The DLA plans to transition to Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, positioning AmerisourceBergen to continue supporting critical pharmaceutical supply requirements across the Defense Department's global operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 12/3/25 |